Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Biogen Idec
 More »

  • Novo Nordisk Reports Promising Phase III Results for Hemophilia...
    ... to bring a recombinant Factor IX to market is Biogen Idec and Swedish Orphan Biovitrum, which last year also published promising Phase III clinical trial results for their product. ...
    5-17-2013
  • Biotechs Need to Walk the Walk on Drug Value
    In June 2012, Massachusetts joined with Abbott, Biogen Idec, EMD Serono, Janssen, Merck & Co., Pfizer, and Sunovion Pharmaceuticals to form the Massachusetts Neuroscience ...
    5-15-2013
  • Biogen Idec Pays Isis $3.5M for Antisense Drug Milestone
    Isis Pharmaceuticals just earned a $3.5 million milestone payment from Biogen Idec associated with the dosing of the first patient in a Phase II study of ISIS-SMN Rx in infants ...
    5-10-2013
  • GEN | Biolinks
    ... Minnesota BioChain BIOCOM Biocrates Life Sciences BioFarmind BioFlorida BioForward Biogen Idec BioMarin Biomedical / Clinical Engineering Association of Ireland Biominas Brasil ...
  • E&Y: Biotechs Must Walk the Walk on Drug Value
    In June 2012, Massachusetts joined with Abbott, Biogen Idec, EMD Serono, Janssen, Merck & Co., Pfizer, and Sunovion Pharmaceuticals to form the Massachusetts Neuroscience ...
    4-22-2013
  • Clock Ticking in Elan Takeover Battle
    Elan or declare it will give up plans to buy the biotech giant for more than double what it gained from selling its 50% share in the multiple sclerosis drug Tysabri to Biogen Idec. ...
    4-3-2013
  • People in the News
    Prior to Avila, Bosley was vp business development at Adnexus Therapeutics. Before that, she was in business development and commercial operations at Biogen Idec. Bernardino ...
    4-1-2013
  • Electronics Giants Set Sights on Biotech
    A month earlier, Samsung Bioepis-a Samsung-Biogen Idec biologics joint venture-said it would collaborate with Merck & Co. to create "multiple pre-specified" undisclosed ...
    4-1-2013
  • Biogen Idec Prepares to Launch 4th MS Drug
    Biogen Idec said yesterday it will launch its newest drug Tecfidera(tm) (dimethyl fumarate) in the U.S. "in the coming days" after winning FDA approval for first-line oral ...
    3-28-2013
  • Biopharmas Cooling to Licensing Deals as Patent Cliff Fears Ease
    ... Even that is less likely, she added; FDA on Wednesday approved Biogen Idec's oral MS drug Tecfidera. Big biopharma spent $20.9 billion on licensing deals in 2012, a 19% drop from ...
    3-28-2013
  • Biosimilars: Not So Far So Fast
    ... Murray, as Merck abandoned its initial effort and restructured around a marketing pact with Samsung and its biotech partner Biogen Idec. And makers of originator drugs seem to have ...
    3-15-2013
  • Elan Cool to Royalty Pharma Offer
    That day, Elan announced an outline of how it would use the $3.25 billion it will receive from selling its half-share of all rights plus royalties to Tysabri to Biogen Idec, with ...
    2-25-2013
  • Top 10 Biopharma Employers with Certified H-1B Workers
    (and subsidiary Genzyme) 2 24 workers certified 2 certified-withdrawn; 1 denied #8. Biogen Idec 25 workers certified #7. Pfizer 28 workers certified 4 certified-withdrawn #6. Merck ...
    2-22-2013
  • Electronics Giant Samsung Makes First Big Biotech Play
    Samsung Bioepis, which is a joint venture formed last year by Samsung Biologics and Biogen Idec to focus on biosimilars, has a R&D center based in Song-do Incheon, Korea. Under the ...
    2-20-2013
  • Nuvilex Lights Up New Medical Marijuana Company
    Also, in March of 2012, Biogen Idec and MAKScientific , a company focused on therapeutics that modulate cannabinoid pathways, entered into an exclusive, worldwide option and ...
    2-12-2013

  • Journal Articles

  • Testicular Uptake and Radiation Dose in Patients Receiving Zevalin...
    Sui Shen, Ruby Meredith, Jun Duan, Andres Forero, Hazel Breitz, M.B. Khazaeli, Ivan Brezovich, Albert LoBuglio
    Cancer Biotherapy and Radiopharmaceuticals
    a Zevalin(tm) (Biogen Idec, Cambridge, MA) regimen and 6 male colorectal cancer patients who received a Pretarget(tm) (Neo Rx, Seattle, WA) CC49Fusion protein were evaluated. ...
  • Effect of Antilymphoma Antibody, 131 I-Lym-1, on Peripheral Blood...
    Orazio Schillaci, Gerald L. DeNardo, Sally J. DeNardo, Desiree S. Goldstein, Linda A. Kroger, Robert T. O'Donnell, Kathleen R. Lamborn
    Cancer Biotherapy and Radiopharmaceuticals
    Cancer Biotherapy and Radiopharmaceuticals ABSTRACT Anti-CD20 monoclonal antibodies (mAbs), unlabeled rituximab (Rituxan®, Biogen Idec Inc., Cambridge, MA; and Genentech Inc., ...
  • Transfer of Interferon β-1a into Human Breastmilk
    Thomas W. Hale, Afzal A. Siddiqui, Teresa E. Baker
    Breastfeeding Medicine
    and provides an estimate of infant exposure to this antiviral in six women chronically receiving intramuscular interferon ß-1a (Avonex®, Biogen Idec, Research Triangle Park, NC). ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll